Mixed Fortunes for Pharma and Bio Stocks: Samchundang Pharmaceuticals and Alteogen Weaken, Hanmi Pharmaceutical Rises to the 420,000-Won Range
Domestic pharmaceutical and bio-related stocks showed mixed movements on the morning of the 2nd. Samchundang Pharmaceuticals and Alteogen on the KOSDAQ fell slightly, while Celltrion, Hanmi Pharmaceutical, and Green Cross on the KOSPI rose. ■ Samchundang Pharmaceuticals and Alteogen decline modestl

Domestic pharmaceutical and bio-related stocks showed mixed movements on the morning of the 2nd. Samchundang Pharmaceuticals and Alteogen on the KOSDAQ fell slightly, while Celltrion, Hanmi Pharmaceutical, and Green Cross on the KOSPI rose.
■ Samchundang Pharmaceuticals and Alteogen decline modestly, down less than 1%
Samchundang Pharmaceuticals was trading at 182,500 won, down 200 won (0.11%) from the previous session. Its intraday high was 186,900 won, its low 170,700 won, and its trading volume was 73,376 shares. Samchundang Pharmaceuticals focuses on drug development and production and has drawn market attention for its pharmaceutical business, including biosimilars.
Alteogen was trading at 215,050 won, down 1,000 won (0.47%) from the previous session. It rose as high as 215,500 won intraday but also fell to 201,000 won. Its trading volume was 136,877 shares. Alteogen develops technologies related to drug administration methods for biopharmaceuticals, with subcutaneous injection formulation conversion technology among its main business areas.
Both stocks were declining, but their losses remained below 1%.
■ Celltrion, Hanmi Pharmaceutical, and other KOSPI pharma stocks gain strength
Celltrion was trading at 193,000 won, up 1,400 won (0.73%) from the previous session, recording an intraday high of 195,400 won, a low of 185,500 won, and a trading volume of 218,053 shares.
Hanmi Pharmaceutical was trading at 425,050 won, up 5,500 won (1.33%). Its intraday high was 433,000 won, its low 397,000 won, and its trading volume was 137,593 shares. Hanmi Pharmaceutical is a major domestic pharmaceutical company engaged in new drug research and development and prescription drug businesses. However, no evidence was confirmed directly linking the day's rise to any specific new drug development achievement or individual positive news.
IGB Pharma (Lee's Pharmaceutical) rose 65 won to 3,500 won (1.89%), Dong-A ST rose 250 won to 34,100 won (0.74%), Daewoong Pharmaceutical rose 200 won to 1,013,000 won (0.20%), and Celltrion Pharm rose 150 won to 36,800 won (0.41%).
■ Prestige Biologics plunges more than 8%, standing out among decliners
Some bio stocks posted steep declines. Prestige Biologics plunged 96 won, or 8.29%, to 1,062 won, falling as low as 1,010 won intraday with a trading volume of 267,086 shares. Prestige Biopharma was trading at 3,795 won, down 225 won (5.60%), with an intraday high of 3,980 won and a low of 3,690 won.
Aprogen fell 43 won, or 2.30%, to 1,827 won; Chong Kun Dang fell 800 won, or 1.27%, to 62,300 won; and Hanall BioPharma fell 400 won, or 1.07%, to 37,100 won. Bynax (VaxnBionax) declined 1.00% to 5,970 won, and SunBio fell 0.95% to 5,200 won. Samsung Epiis Holdings was trading at 308,000 won, down 1,500 won (0.48%).
In the recent pharmaceutical and bio market, clinical trial progress, technology transfer agreements, and the sales and profitability of key drugs are cited as important evaluation factors for new drug developers. Due to the nature of the industry, companies differ in their drug development stages, key products, technology transfer agreements, and production and sales structures, which can lead to divergent stock price movements. In particular, announcements related to clinical trials carry different meanings depending on the stage of progress, such as trial plan approval, announcement of clinical results, or product approval.
[This article is for investment reference only and does not recommend the purchase or sale of any specific stock. The final judgment and responsibility for investments rest with the investor. This article was written with some assistance from AI.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



